Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: Case report and review of literature

Prasad, Hari; Kaushal, Varsha; Mehta, Paulette

doi:10.1002/ajh.20949

Cited by 8 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,6 Other drugs induce thrombocytopenia as a major side effect by affecting platelet production in the bone marrow through direct myelosupression. 7,8 Thrombocytopenia can also be associated with chronic infections such as HIV 9 or hepatitis C 10 or may be an accessory syndrome of hereditary diseases. [11][12][13] Generally, medical treatment of thrombocytopenia with functional platelets is indicated in adult patients with a platelet count of ,30 platelets/nL blood.…”

Section: Introductionmentioning

confidence: 99%

Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice

Morowski

Vögtle

Kraft

et al. 2013

Blood

117

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice

Morowski

Vögtle

Kraft

et al. 2013

Blood

117

View full text Add to dashboard Cite

show abstract

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

Downs

Judson

Argenta

et al. 2007

Cancer

View full text Add to dashboard Cite

Zoledronic acid (ZOL), an intravenous bisphosphonate, has been shown to reduce and delay the incidence of skeletal‐related events (SREs) in multiple myeloma (MM) patients with bone disease. A retrospective claims‐based analysis was conducted that used two distinct US managed care databases to examine the relationship between persistency with ZOL and clinical benefit. Patients >18 years, diagnosed with MM, and with at least one claim for ZOL (or a claim for malignant bone disease and ZOL initiation within 30 days) between 1/1/2001 and 12/31/2006 were included. Patients were evaluated for incidence of SREs and for mortality. Treatment persistency was defined as the absence of a >45 day gap between ZOL administrations. Of 1,655 patients in this analysis, 1,060 received ZOL and 595 received no intravenous bisphosphonate therapy. Compared with patients not receiving bisphosphonate therapy, ZOL‐treated patients had lower incidences of SREs (P < 0.0001) and death (P = 0.0001). Longer persistency with ZOL was associated with lower risks of SREs (P = 0.001), fracture (P = 0.003), and death (P = 0.002) versus shorter persistency. Patients who were persistent with ZOL for ≥1.5 years had an incidence of 15.0 SREs and 6.2 fractures per 100 person‐years. Patients who were persistent for 31–90 days had an incidence of 24.6 SREs and 14.0 fractures per 100 person‐years, and patients not receiving intravenous bisphosphonates had an incidence of 32.2 SREs and 16.9 fractures per 100 person‐years. These data from a real‐world setting indicate that among MM patients, longer persistency with ZOL was associated with a lower risk of SREs and fracture. Am. J. Hematol. 87:490–495, 2012. © 2012 Wiley Periodicals, Inc.

show abstract

Current awareness: Pharmacoepidemiology and drug safety

2008

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 20 sections: 1 Reviews; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Teratogens/fetal exposure; 20 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Isolated thrombocytopenia induced by thalidomide in a patient with multiple myeloma: Case report and review of literature

Cited by 8 publications

References 11 publications

Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice

Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice

A prospective randomized trial of thalidomide with topotecan compared with topotecan alone in women with recurrent epithelial ovarian carcinoma

Current awareness: Pharmacoepidemiology and drug safety

Contact Info

Product

Resources

About